These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21365101)

  • 1. Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist.
    Liu J; Deng X; Fitzgerald AE; Sales ZS; Venkatesan H; Mani NS
    Org Biomol Chem; 2011 Apr; 9(8):2654-60. PubMed ID: 21365101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
    Pippel M; Boyce K; Venkatesan H; Phuong VK; Yan W; Barrett TD; Lagaud G; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6376-8. PubMed ID: 19815410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
    Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats.
    Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M
    Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK1 and 2 receptors are expressed in immortalized rat brain neuroblasts: intracellular signals after cholecystokinin stimulation.
    Langmesser S; Cerezo-Guisado MI; Lorenzo MJ; Garcia-Marin LJ; Bragado MJ
    J Cell Biochem; 2007 Mar; 100(4):851-64. PubMed ID: 17226751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of luminal gastrin in the regulation of pancreatic juice secretion in preruminant calves.
    Zabielski R; Normand V; Romé V; Woliński J; Chayvialle JA; Guilloteau P
    Regul Pept; 2004 Jul; 119(3):169-76. PubMed ID: 15120477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon.
    Fornai M; Colucci R; Antonioli L; Baschiera F; Ghisu N; Tuccori M; Gori G; Blandizzi C; Del Tacca M
    Eur J Pharmacol; 2007 Feb; 557(2-3):212-20. PubMed ID: 17208221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of concise, scalable route to a cholecystokinin 1 (CCK 1) receptor antagonist.
    Liang JT; Mani NS; Jones TK
    J Org Chem; 2007 Oct; 72(22):8243-50. PubMed ID: 17887796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
    J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
    Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
    J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parasympathetic non-adrenergic, non-cholinergic transmission in rat parotid glands: effects of cholecystokinin-A and -B receptor antagonists on the secretory response.
    Ekström J; Cevik Aras H
    Regul Pept; 2008 Feb; 146(1-3):278-84. PubMed ID: 18006087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An expedient route to a potent gastrin/CCK-B receptor antagonist (+)-AG-041R.
    Sato S; Shibuya M; Kanoh N; Iwabuchi Y
    J Org Chem; 2009 Oct; 74(19):7522-4. PubMed ID: 19719158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists.
    Roberts K; Ursini A; Barnaby R; Cassarà PG; Corsi M; Curotto G; Donati D; Feriani A; Finizia G; Marchioro C; Niccolai D; Oliosi B; Polinelli S; Ratti E; Reggiani A; Tedesco G; Tranquillini ME; Trist DG; van Amsterdam FT
    Bioorg Med Chem; 2011 Jul; 19(14):4257-73. PubMed ID: 21689940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-ones and their evaluation as cholecystokinin-ligands.
    Offel M; Lattmann P; Singh H; Billington DC; Bunprakob Y; Sattayasai J; Lattmann E
    Arch Pharm (Weinheim); 2006 Apr; 339(4):163-73. PubMed ID: 16572480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
    Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
    J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient asymmetric synthesis of novel gastrin receptor antagonist AG-041R via highly stereoselective alkylation of oxindole enolates.
    Emura T; Esaki T; Tachibana K; Shimizu M
    J Org Chem; 2006 Oct; 71(22):8559-64. PubMed ID: 17064034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
    J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of CCK1 cholecystokinin receptors in normal and neoplastic human tissues.
    Schulz S; Röcken C; Mawrin C; Schulz S
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6149-55. PubMed ID: 16105969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
    Rosen MD; Hack MD; Allison BD; Phuong VK; Woods CR; Morton MF; Prendergast CE; Barrett TD; Schubert C; Li L; Wu X; Wu J; Freedman JM; Shankley NP; Rabinowitz MH
    Bioorg Med Chem; 2008 Apr; 16(7):3917-25. PubMed ID: 18289861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.